Ambry launches StemArray for characterising human stem cells
This article was originally published in Clinica
Ambry Genetics has launched its StemArray product and services for detecting abnormalities in human stem cells. The test uses array comparative genomic hybridisation (aCGH) technology to cover the entire genome, detecting defects that are missed by conventional low-resolution karyotyping, the Aliso Viejo, California firm claims. StemArray is designed for use with human embryonic and induced pluripotent stem cells, which are susceptible to chromosomal instability when cultured for long periods of time. These abnormalities can decrease the reproducibility and reliability of experimental data. Ambry is offering the product at a comparable cost to traditional karyotyping, it said.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.